Brian Elliott

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Catherine Thiéblemont, Tycel Phillips, Hervé Ghesquières et al. · Journal of Clinical Oncology · 2022 · 484 citations · Full text

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

Martin Hutchings, Rogier Mous, Michael Roost Clausen et al. · The Lancet · 2021 · 315 citations · Full text

Subcutaneous Epcoritamab, Lymphoid Neoplasia, Dose Escalation +4

Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

Kim Linton, Umberto Vitolo, Wojciech Jurczak et al. · The Lancet Haematology · 2024 · 111 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Medicine +8

Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data

Martin Hutchings, Rogier Mous, Michael Roost Clausen et al. · Blood · 2020 · 64 citations

Combining FDG-PET/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma*

Brian Elliott, Steven Peti, Keren Osman et al. · European Journal Of Haematology · 2011 · 38 citations